Drugmakers may need designated expert to certify batches before sale
LiveMint

The development assumes significance for India's $60-billion pharmaceutical
industry amid concerns over the quality of drugs manufactured in the country.
LiveMint

The development assumes significance for India's $60-billion pharmaceutical
industry amid concerns over the quality of drugs manufactured in the country.
Several outlets reported this. AI can compare where they agree and differ.
IndiaTimes of India
The Health Ministry has introduced new regulations aimed at suspending manufacturing licenses for medicines that do not meet quality criteria. This swift action is intended to stop subpar drugs from reaching patients and to minimize their circulation during the regulatory review. Licenses can be suspended based on government analysts' findings that indicate deficiencies.
IndiaLiveMint
The Centre plans to upgrade high-performing Jan Aushadhi Kendras into modern flagship outlets with a better drug portfolio, redesigned store layouts and enhanced credit facilities
EconomyThe Hindu BusinessLine
India's chemical industry is positioned for strong growth and global expansion driven by a significant investment push.
EconomyFirstpost
The trade agreement could open Europe's market to Indian textiles, footwear, engineering goods and services. But businesses will have to overcome certification, quality and supply-chain challenges to turn lower tariffs into actual orders
Hindustan Times
The restriction is intended to prevent manufacturers from using product names and promotional language that create an impression of medical efficacy without regulatory approval or scientific substantiation.
IndiaLiveMint
The NPPA ordered strict checks to ensure price cuts of up to 90 percent on 137 cancer drugs reach patients.
MarketsCNBC-TV18
Aurobindo Pharma said the USFDA had inspected the facility from August 17 to August 21, 2026, and issued four observations following the inspection. The company said it had responded to all four observations within the stipulated time.
TechnologyLiveMint
The DCGI ordered the halt in production and recall of obeticholic acid tablets following similar global regulatory actions.